Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Dr. Monk on the Growing Role of Checkpoint Inhibitors in Cervical Cancer

May 4th 2022

Bradley J. Monk, MD, FACS, FACOG, discusses the growing role of checkpoint inhibitors in cervical cancer.

European Commission Approves Pembrolizumab/Chemotherapy With or Without Bevacizumab for PD-L1+ Metastatic Cervical Cancer

April 29th 2022

The European Commission has granted an approval to the combination of pembrolizumab and chemotherapy, with or without bevacizumab, for the treatment of adult patients with persistent, recurrent or metastatic cervical cancer whose tumors have a PD-L1 combined positive score of 1 or higher.

European Commission Approves Pembrolizumab for Select MSI-H/dMMR Solid Tumors

April 29th 2022

The European Commission has granted an approval to pembrolizumab for the treatment of patients with select microsatellite instability–high or deficient mismatch repair solid tumors.

Novel FSHR-Mediated CAR T Approach Under Exploration in Recurrent Ovarian Cancer

April 28th 2022

An investigative follicle-stimulating hormone receptor–mediated CAR T-cell technology is under exploration in patients with recurrent ovarian cancer.

Neoadjuvant Chemoimmunotherapy Demonstrates Activity in Advanced Ovarian Cancer

April 13th 2022

The addition of durvalumab and tremelimumab to chemotherapy led to encouraging responses and a suitable safety profile as neoadjuvant therapy in patients with advanced ovarian cancer, according to findings from the phase 2 KGOG 3046.

Addition of NG-641 to Nivolumab Under Exploration in Epithelial Tumors

April 12th 2022

The combination of the novel adenoviral vector NG-641 and nivolumab is being investigated in patients in the phase 1a/b NEBULA trial in patients with previously treated metastatic or advanced epithelial tumors.

ZN-c3 Shows Preliminary Efficacy, Safety in Recurrent/Advanced Uterine Serous Carcinoma

April 12th 2022

The investigational Wee1 inhibitor ZN-c3 was found to be safe and to produce a disease control rate of 90.9% and an objective response rate of 27.3% in patients with advanced or recurrent uterine serous carcinoma.

Olaparib Combination Shows Notable Non-Progression Rate in Endometrial Cancer

April 11th 2022

In the ENDOLA trial, olaparib in combination with metronomic cyclophosphamide and metformin showed a significant non-progression rate in patients with recurrent advanced or metastatic endometrial cancer.

Study Reveals Increased Disparities in Cervical Cancer Screening Linked With COVID-19 Pandemic

April 7th 2022

Women of all races and ethnicities who were referred to a colposcopy clinic for cervical cancer screening following an abnormal Pap smear during the COVID-19 pandemic had a higher likelihood of not adhering to their appointment compared with appointment data collected prior to the pandemic.

Matulonis’ Passion Drives Gynecologic Cancer Research Into the Next Era

April 7th 2022

Specialization in oncology research affords investigators the opportunity to dive into tumor biology and uncover unique approaches to care.

Ongoing Clinical Trials for Patients With Endometrial Cancer: Looking Toward the Future

April 5th 2022

Experts highlight key ongoing trials and emerging therapies for patients with endometrial cancer.

Sequencing Therapy for MSI-High and MMR-Proficient Endometrial Carcinomas

April 4th 2022

A discussion on the best way to sequence therapies for patients with MSI-high and MMR-proficient endometrial carcinoma.

Relacorilant/Nab-Paclitaxel Combo Improves OS in Recurrent, Platinum-Resistant Ovarian Cancer

March 31st 2022

The addition of relacorilant to nab-paclitaxel improved overall survival compared with nab-paclitaxel alone in patients with recurrent, platinum-resistant ovarian cancer.

Frontline Maintenance Rucaparib Significantly Improves PFS in Ovarian Cancer Irrespective of Biomarker Status

March 31st 2022

Rucaparib significantly improved investigator-assessed progression-free survival over placebo when used as maintenance treatment in newly diagnosed patients with advanced ovarian cancer following successful first-line treatment with platinum-based chemotherapy, according to top-line findings from the monotherapy arm of the phase 3 ATHENA trial.

Management of Adverse Events After Combination Lenvatinib/Pembrolizumab

March 29th 2022

Shared insight on the management of commonly observed adverse events in patients with endometrial cancer who are receiving combination lenvatinib/pembrolizumab.

Treatment Modification Rates for Combination Lenvatinib/Pembrolizumab

March 29th 2022

A brief review of treatment interruption, discontinuation, and dose modification rates in patients receiving combination lenvatinib/pembrolizumab in the KEYNOTE-775 trial or in the experts’ clinical practice.

Pembrolizumab Plus Chemo With or Without Bevacizumab Approaches EU Approval for Select Cervical Cancer

March 28th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of pembrolizumab for use in combination with chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer who have a PD-L1 combined positive score of 1 or higher.

Concurrent Durvalumab/Chemoradiation Misses PFS End Point in Locally Advanced Cervical Cancer

March 24th 2022

Durvalumab given concurrently with chemoradiation was not found to significantly improve progression-free survival vs chemoradiation alone in patients with locally advanced cervical cancer, missing the primary end point of the phase 3 CALLA trial.

Endometrial Carcinoma: Clinical Case Scenario 3

March 24th 2022

Oncologists debate the proper treatment of a patient with a grade 2 endometrial carcinoma tumor.

Trastuzumab in Endometrial Carcinoma Therapy

March 24th 2022

Dr David O’Malley explains when to add and remove trastuzumab during endometrial carcinoma therapy.